^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Published date:
05/15/2020
Excerpt:
Therapeutic testing in mice revealed that both erlotinib and afatinib caused regression of osimertinib-resistant C797S-containing tumors, whereas only afatinib was effective on L718Q mutant tumors.
DOI:
10.1158/0008-5472.CAN-19-3819